my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
04-08-2009: Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced that the European Commission has approved the Marketing Authorisation Application for the company’s oral once-daily medication Samsca™(tolvaptan), a selective V2-vasopressin receptor antagonist, for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults. Samsca is the first oral vasopressin receptor antagonist available in Europe.
Results from the SALT-1 and SALT-2 (Study of Ascending Levels of Tolvaptan in Hyponatraemia -1 and -2 ) trial programme showed that once-daily oral tolvaptan was effective in increasing serum sodium concentrations in patients with SIADH.
Samsca is a novel molecule designed to be an orally available antagonist of the vasopressin V2 receptor, which plays a role in the kidney’s regulation of fluid excretion. Samsca is designed to promote aquaresis, the excretion of electrolyte-free water.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
European Commission authorizes EU-wide marketing and distribution of Biofrontera's Ameluz
Biofrontera was informed by the European Commission that its product Ameluz® (in development called BF-200 ALA) was approved for distribution throughout the entire EU, Norway, Island and Liechtenstein. Already in October had the responsible "European Medicines Agency" recommended the approv ... more
Takeda Pharmaceutical Company Limited announced that the European Commission has granted marketing authorisation for Edarbi® (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB) (also known as angiotensin II receptor antagonist [AIIRA]) for the treatment of essential ... more
Cellzome Founder wins EU Women Innovators Award
Cellzome announced that Dr. Gitte Neubauer, one of the scientific founders of Cellzome, has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome ... more
Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutic ... more
Otsuka Pharmaceutical Co., Ltd. and UCB announced that the companies have agreed to focus their collaboration on the therapeutic area of Central Nervous System (CNS) disorders and to discontinue their collaboration in immunology. The companies will end their co-development and co-promotion ... more
E Keppra (levetiracetam) receives regulatory approval in Japan
Otsuka Pharmaceutical Co., Ltd. and UCB announced that UCB Japan has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® (250 mg and 500 mg Tablets). E Keppra® has been approved in Japan as adjunctive therapy in the trea ... more
Otsuka Pharmaceutical Co., Ltd. and UCB announced that the companies have agreed to focus their collaboration on the therapeutic area of Central Nervous System (CNS) disorders and to discontinue their collaboration in immunology. The companies will end their co-development and co-promotion ... more
E Keppra (levetiracetam) receives regulatory approval in Japan
Otsuka Pharmaceutical Co., Ltd. and UCB announced that UCB Japan has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® (250 mg and 500 mg Tablets). E Keppra® has been approved in Japan as adjunctive therapy in the trea ... more
European Commission approves Samsca for Hyponatraemia
Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced that the European Commission has approved the Marketing Authorisation Application for the company’s oral once-daily medication Samsca™(tolvaptan), a selective V2-vasopressin receptor antagonist, for the t ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
